oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 5 )

2018 ( 41 )

2017 ( 35 )

2016 ( 41 )

Custom range...

Search Results: 1 - 10 of 2040 matches for " ACE inhibitors "
All listed articles are free for downloading (OA Articles)
Page 1 /2040
Display every page Item
Synthesis of angiotensin-converting enzyme (ACE) inhibitors: an important class of antihypertensive drugs
Lima, Dênis Pires de;
Química Nova , 1999, DOI: 10.1590/S0100-40421999000300016
Abstract: this report outlines the discovery, the design and development of new compounds, and, structure-activity relationships for this drug category. updated approaches to planned syntheses of new worthy ace-inhibitors are also exploited.
Synthesis of angiotensin-converting enzyme (ACE) inhibitors: an important class of antihypertensive drugs
Lima Dênis Pires de
Química Nova , 1999,
Abstract: This report outlines the discovery, the design and development of new compounds, and, structure-activity relationships for this drug category. Updated approaches to planned syntheses of new worthy ACE-inhibitors are also exploited.
Some aspects of the lisinopril usage in arterial hypertension treatment
N.A. Jaiani
Rational Pharmacotherapy in Cardiology , 2010,
Abstract: The evidence basis and advantages of the lisinopril usage in a clinical practice as antihypertensive drug are presented. Special attention is paid to organoprotective lisinopril effects and lisinopril implementation at special clinical conditions (chronic obstructive pulmonary disease comorbidity, elderly patients, and concomitant liver diseases).Pharmacoeconomic aspects of lisinopril usage in arterial hypertension are also considered.
"Pharmacodynamically evaluated bioequivalence of two preparations of Enalapril Maleate "
"Tajerzadeh H,Hamidi M,Rouini MR,Shahverdi M
DARU : Journal of Pharmaceutical Sciences , 2001,
Abstract: The bioequivalence of two preparations of enalapril maleate (20 mg tablets) manufactured in Iran has been exploited in reference to a standard preparation (Xanef 20 tablets, MSD, Germany) in 14 healthy volunteers. Following oral dosing of a single tablet of each of test and standard products, as a randomized crossover design with 10-day washout intervals, the blood samples were collected in predetermined time points and using a synthetic substrate, Hippuryl-Histidy-Leucine (HHL), the release of hippuric acid from the substrate was determined as Angiotensin-Converting-Enzyme (ACE) activity of serum fractions. The percent of ACE inhibition in each sample was calculated and plotted against time, from which three pharmacodynamic parameters, i.e. Emax, tmax and AUC0-24 were derived. The results of statistical comparison of these parameters showed that both of the test preparations are bioequivalent with reference standard preparation.
ACE inhibitors in arterial hypertension treatment: focus on lisinopril
V.I.Podzolkov,K.K.Osadchy
Rational Pharmacotherapy in Cardiology , 2009,
Abstract: Approaches to the choice of antihypertensive pharmacotherapy are discussed. Evidence base of ACE inhibitor lisinopril is surveyed. Data about lisinopril effects on different endpoints, organoprotective action and advantages over other ACE inhibitors are presented.
Dose response of ACE inhibitors: implications of the SECURE trial
Eva Lonn
Trials , 2001, DOI: 10.1186/cvm-2-4-155
Abstract: Angiotensin-converting enzyme (ACE) inhibitors have been used extensively in the management of hypertension and heart failure. Recent trials, primarily the Heart Outcomes Prevention Evaluation (HOPE) study, also demonstrate a clear role for these agents in reducing the risk for adverse cardiovascular outcomes in patients without heart failure and with preserved left ventricular (LV) ejection fraction [1]. Experimental research and recent clinical studies also show favorable effects of ACE inhibitor therapy on the arterial vascular wall. The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE), a substudy of the HOPE trial, thus demonstrated reduced progression of carotid atherosclerosis in patients treated with ramipril [2]. Other investigations have revealed improved endothelial function in patients receiving ACE inhibitors [3,4].What are 'optimal' doses of ACE inhibitors to be used in different clinical settings? This question is encountered frequently by clinicians and remains controversial. A number of surveys suggest that clinicians often prefer the use of low doses of ACE inhibitors, and the perception that low doses are as effective as high ones is quite prevalent. In addition, clinicians frequently titrate ACE inhibitor dose according to blood pressure and rely on 'adequate' blood pressure control as a marker of the effectiveness of this therapy, not only in patients treated for hypertension, but also in those treated for heart failure and for reduction of cardiovascular risk.In this commentary, several lines of evidence have been extracted from clinical trials in chronic heart failure, coronary artery disease (CAD) and atherosclerosis to show that the size of the ACE inhibitor dose matters, higher doses are more effective than lower doses and the duration of therapy is important.Several clinical trials in heart failure have specifically addressed the question of optimal ACE inhibitor dose (Table 1) [5,6,7,8].
?Es segura la combinacion de ieca o ara II con espironolactona?
Restrepo,César A;
Acta Medica Colombiana , 2005,
Abstract: objectives: to determine if in patients evaluated by hyperkalemia in a nephrology service the combination ace inhibitors or angiotensin receptor blocker with spironolactone was present and what consequences it had on the group of identified patients. design: study of retrospective, prospective, observational and descriptive type. place: renal unit str (service of renal therapy) of caldas, hospital santa sofia, manizales. population: all the patients interconsulted to the service of renal therapy of caldas to present hyperkalemia. materials: the clinical histories of the patients interconsulted to the str of caldas were revised initially retrospectively and then prospectively because they present hyperkalemia, the next step was to proceed to discard those patients that presented illness renal chronic stadium 4 and 5, next the ones that had been receiving the combination ace inhibitors or angiotensin receptor blocker with spironolactone were identified, their evolution, complications and predisposition factors were established. results: 17 patients fulfilled the requirements for this work, 8 males and 9 females, mean age 65 years, 7 presented diabetes mellitus and 10 presented essential hypertension, 12 patients had cardiac illness of some type, 2 with base nephropathy (diabetic and hypertensive), 3 with rheumatologic disease and 1 with cirrhosis, among the factors that predispose to hyperkalemia, the following were detected: sharp decrease of renal perfusion in 5, active infection in 3, sharp obstructive nephropathy in one, and a new medication that affected renal secretion of potassium in two. ten patients required hospitalization in the intensive care unit, with an average time of hospitalization of 7 days. 12 patients required hemodialysis and 5 died in the first 24 hours due to refractory shock because of therapies with vasoconstrictors and inotropic drugs. the concomitant use of medications that inhibited the renin-angiotensin-aldosterone axis was very frequent.
State of renal hemodynamics and nephrofibrosis parameters in patients with nephrolithiasis applying angiotensin converting enzyme inhibitors
P.V. Glybochko,A.A. Svistunov,A.N. Rossolovsky,O.L. Berezinetz
Saratov Journal of Medical Scientific Research , 2010,
Abstract: The aim of the study is to evaluate the influence of angiotensin converting enzyme (ACE) inhibitors of quinapril on the condition of renal hemodynamics, changes of profibrotic cytokines level and transforming growth factor at patients with nephrolithiasis undergone various kinds of surgery. Patients were divided into 2 groups initially and in 1 month after surgery. Concentrations of IL-6, TGFp and МСР-1 were determined in blood serum. Assessment of renal blood flow state by Doppler ultrasonography was performed in the same terms. As a result of quinapril treatment the decrease of МСР-1, TGFp and IL-6 was marked in comparison with the group which did not receive nephroprotective therapy. The analysis of Doppler ultrasonography data showed authentic improvement of renal blood flow in 1 month after surgery. The most informative parameter proved to be the resistance index that indicated the decrease of vascular resistance after surgical treatment in condition of quinapril therapy
Angiotensin converting enzyme inhibitors in management of patients with chronic heart failure
S.N. Tereshchenko,N.A. Dzhaiani
Rational Pharmacotherapy in Cardiology , 2009,
Abstract: The role of ACE inhibitors in modern pharmacotherapy of patients with chronic heart failure (CHF) is discussed. The actual usage of these highly effective drugs is underlined taking into account high prevalence and social significance of CHF. Necessity of ACE inhibitors usage is confirmed by pharmacodynamic features of these drugs in CHF. The special attention is given to enalapril, that has the biggest evidence base in treatment of CHF patients.
ACE inhibitors in patients with ischemic heart disease without heart failure: class effects and efficacy of its representatives
Y.A. Karpov
Rational Pharmacotherapy in Cardiology , 2005,
Abstract: Results of large-scale studies (QUIET, HOPE, EUROPA, PEACE, CAMELOT), devoted to assessment of the role of ACE inhibitors in treatment of patients with stable form of ischemic heart disease without heart failure are analyzed. Different efficacy of the representatives of this class toward risks of coronary events development and cerebral-vascular complications is shown, as well as the overall mortality risk due to cardiovascular reasons. Favorable therapeutic effects of inhibiting RAS activity in patients without left ventricle dysfunction are demonstrated in studies EUROPA with perindopril 8 mg, and HOPE with ramipril 10 mg. That became the ground of inclusion of these drugs into recommendations for treatment of all patients with ischemic heart disease after myocardial infarction, in addition to antiplatelet, lipid reducing remedies and beta-blockers.
Page 1 /2040
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.